Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1633]
News [6491]
Articles [98]
Editorials [4]
Conferences [184]
elearning [21]
Custirsen shows no survival benefit in metastatic prostate cancer
Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France
Custirsen shows no survival benefit in metastatic prostate cancer ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )
10 Oct 2016
Significant survival gains for neoadjuvant chemotherapy for high risk soft...
Dr Alessandro Gronchi - National Cancer Institute, Milan, Italy
Significant survival gains for neoadjuvant chemotherapy for high risk soft tissue sarcoma ( Dr Alessandro Gronchi - National Cancer Institute, Milan, Italy )
10 Oct 2016
Cabozantinib over sunitinib for metastatic renal cell carcinoma
Dr Toni Choueiri - Dana Farber Cancer Institute, Boston, USA
Cabozantinib over sunitinib for metastatic renal cell carcinoma ( Dr Toni Choueiri - Dana Farber Cancer Institute, Boston, USA )
10 Oct 2016
Negative trial results of custirsen for metastatic prostate cancer
Prof Karim Fizazi - Cancer Medicine at the Institut Gustave Roussy, Villejuif...
Negative trial results of custirsen for metastatic prostate cancer ( Prof Karim Fizazi - Cancer Medicine at the Institut Gustave Roussy, Villejuif, France )
10 Oct 2016
Cabozantinib improves PFS in metastatic renal cell carcinoma
Dr Toni Choueiri - Dana Farber Cancer Institute, Boston, USA
Cabozantinib improves PFS in metastatic renal cell carcinoma ( Dr Toni Choueiri - Dana Farber Cancer Institute, Boston, USA )
10 Oct 2016
Advances for NSCLC in review
Dr Stefan Zimmermann - Hôpital Fribourgeois, Fribourg, Switzerland
Advances for NSCLC in review ( Dr Stefan Zimmermann - Hôpital Fribourgeois, Fribourg, Switzerland )
9 Oct 2016
Ceritinib following crizotinib relapse for ALK positive NSCLC
Dr Giorgio Scagliotti - University of Turin, Turin, Italy
Ceritinib following crizotinib relapse for ALK positive NSCLC ( Dr Giorgio Scagliotti - University of Turin, Turin, Italy )
9 Oct 2016
Atezolizumab v docetaxel for NSCLC: results from the OAK trial
Dr Fabrice Barlesi - Hôpital Nord, Marseille, France
Atezolizumab v docetaxel for NSCLC: results from the OAK trial ( Dr Fabrice Barlesi - Hôpital Nord, Marseille, France )
9 Oct 2016
Significant survival gains with atezolizumab for NSCLC
Dr Fabrice Barlesi - Hôpital Nord, Marseille, France
Significant survival gains with atezolizumab for NSCLC ( Dr Fabrice Barlesi - Hôpital Nord, Marseille, France )
9 Oct 2016
Pembrolizumab new option for firstline treatment of advanced lung cancer with...
Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany
Pembrolizumab new option for firstline treatment of advanced lung cancer with high PDL-1 expression ( Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany )
9 Oct 2016
KRAS in the clinic and conference
Dr Ana Vivancos - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
KRAS in the clinic and conference ( Dr Ana Vivancos - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
9 Oct 2016
A potential prognostic biomarker of chemoresistance in mCRC treated with FUFIRI...
Dr Arndt Stahler - University of Munich, Munich, Germany
A potential prognostic biomarker of chemoresistance in mCRC treated with FUFIRI or mIrOx (FIRE1) ( Dr Arndt Stahler - University of Munich, Munich, Germany )
9 Oct 2016

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation